Home » Stocks » Omeros

Omeros Corporation (OMER)

Stock Price: $11.52 USD -0.01 (-0.04%)
Updated Oct 19, 2020 11:11 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 707.23M
Revenue (ttm) 100.34M
Net Income (ttm) -108.01M
Shares Out 61.42M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $11.52
Previous Close $11.52
Change ($) -0.01
Change (%) -0.04%
Day's Open 11.55
Day's Range 11.40 - 11.75
Day's Volume 110,335
52-Week Range 8.50 - 25.46

More Stats

Market Cap 707.23M
Enterprise Value 888.76M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 61.42M
Float 58.70M
EPS (basic) -2.06
EPS (diluted) -2.07
FCF / Share -1.42
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 12.36M
Short Ratio 7.84
Short % of Float 21.06%
Beta 1.62
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.05
PB Ratio n/a
Revenue 100.34M
Operating Income -86.16M
Net Income -108.01M
Free Cash Flow -77.54M
Net Cash -181.53M
Net Cash / Share -2.96
Gross Margin 39.85%
Operating Margin -85.87%
Profit Margin -107.60%
FCF Margin -77.28%
ROA -67.13%
ROE n/a
ROIC -34.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$24.50*
(112.77% upside)
Low
12.0
Current: $11.52
High
34.0
Target: 24.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11229.8764.8341.6213.510.541.606.024.522.11
Revenue Growth274.33%-53.93%55.77%208.07%2406.31%-66.31%-73.43%33.11%114.92%-
Gross Profit11129.3663.7540.2112.470.541.606.024.522.11
Operating Income-63.38-112-43.90-54.28-71.24-70.01-38.02-36.89-27.41-30.11
Net Income-84.49-127-53.48-66.75-75.10-73.67-39.80-38.44-28.55-29.25
Shares Outstanding49.5248.5845.5440.4537.5633.2328.5624.1622.2121.42
Earnings Per Share-1.71-2.61-1.17-1.65-2.00-2.22-1.39-1.59-1.29-1.37
Operating Cash Flow-60.07-104-36.23-51.50-65.21-58.04-29.70-34.55-25.67-14.50
Capital Expenditures-0.33-0.57-0.35-0.13-0.24-0.03-0.20-0.64-1.24-0.81
Free Cash Flow-60.41-104-36.58-51.63-65.45-58.07-29.90-35.19-26.91-15.31
Cash & Equivalents60.7960.5083.7545.3338.947.5714.7823.0324.7642.19
Total Debt19415184.6179.7149.8432.4520.5020.1019.4510.26
Net Cash / Debt-133-90.95-0.86-34.38-10.90-24.89-5.722.935.3231.93
Assets13795.9411667.2849.0010.8316.5426.5826.9845.70
Liabilities24619611910575.2353.4934.9233.1132.5425.23
Book Value-109-100-2.81-37.45-26.23-42.65-18.38-6.53-5.5520.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Omeros Corporation
Country United States
Employees 258
CEO Gregory A. Demopulos

Stock Information

Ticker Symbol OMER
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: OMER
IPO Date October 8, 2009

Description

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.